
Alivus Life Sciences Ltd is Rated Buy
2026-11-13 10:10:45Alivus Life Sciences Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 30 October 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 13 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read MoreAlivus Life Sciences Gains 5.17%: 4 Key Factors Driving the Week
2026-11-07 12:02:47Key Events This Week 2 Nov: New 52-week high at Rs.1,504 4 Nov: Stock hits Rs.1,504.3 amid market rally 5 Nov: New 52-week high at Rs.1,532.95 despite slight intraday dip 6 Nov: Week closes at Rs.1,480.55 (-1.12% on day) Week OpenRs.1,407.80 Week CloseRs.1,480.55<div class="stat-change po...
Read More
Broad-Based Technical Strength Lifts Alivus Life Sciences Ltd to 52-Week High of Rs 1532.95
2026-11-05 10:20:29Surging to a new 52-week and all-time high of Rs 1,532.95 on 5 Nov 2026, Alivus Life Sciences Ltd has demonstrated remarkable price momentum, outpacing the Sensex’s subdued performance over the past year. The stock’s 64.52% gain contrasts sharply with the Sensex’s 5.53% decline, underscoring a strong technical rally amid a broadly positive market backdrop.
Read More
Broad-Based Technical Strength Lifts Alivus Life Sciences Ltd to 52-Week High of Rs 1504.3
2026-11-04 10:00:14Surging to a new all-time peak of Rs 1504.3 on 4 Nov 2026, Alivus Life Sciences Ltd has demonstrated remarkable price momentum, outperforming the broader market with a 62.64% gain over the past year against the Sensex’s decline of 7.41%. This milestone caps a sustained rally that has seen the stock climb steadily from its 52-week low of Rs 830, reflecting a strong alignment of technical indicators across multiple timeframes.
Read More
Alivus Life Sciences Ltd is Rated Buy by MarketsMOJO
2026-11-02 10:10:25Alivus Life Sciences Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 30 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 November 2026, providing investors with the latest insights into its performance and outlook.
Read MoreAlivus Life Sciences Gains 12.87%: 3 Key Factors Driving the Surge
2026-10-31 12:02:24Key Events This Week 26 Oct: Stock opens week at Rs.1,262.20, up 1.19% 27 Oct: Strong 6.44% jump to Rs.1,343.45 amid valuation upgrade talk 28 Oct: Valuation shifts to expensive; stock closes at Rs.1,400.50 (+4.25%) 29 Oct: Slight dip of 0.20% to Rs.1,397.75 despite Sensex rally 30 Oct: New 52-week high at Rs.1,497; closes at Rs.1,407.80 (+0.72%) Week OpenRs...
Read More
Alivus Life Sciences Ltd Reports Strong Quarterly Upswing Amid Positive Financial Trend
2026-10-30 11:00:27Alivus Life Sciences Ltd has demonstrated a marked improvement in its financial performance for the quarter ended September 2026, signalling a positive shift in its growth trajectory. The company’s latest results reveal record highs across key profitability metrics, reflecting robust operational efficiency and a favourable market environment within the Pharmaceuticals & Biotechnology sector.
Read More
Alivus Life Sciences Ltd Valuation Shifts Amid Strong Market Performance
2026-10-28 08:01:04Alivus Life Sciences Ltd has witnessed a notable shift in its valuation parameters, moving from a previously fair valuation to an expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the stock’s price attractiveness relative to its historical averages and peer group benchmarks within the Pharmaceuticals & Biotechnology sector.
Read More
Alivus Life Sciences Ltd is Rated Hold
2026-10-22 10:10:49Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 4 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 October 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.
Read MoreAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19-Nov-2026 | Source : BSEPlease find enclosed herewith intimation for Analyst/Investor meeting.
Announcement Under Regulation 30 - Updates
11-Nov-2026 | Source : BSEPlease find enclosed herewith disclosure under Regulation 30 of SEBI(LODR) 2015.
Announcement under Regulation 30 (LODR)-Updates on Acquisition
11-Nov-2026 | Source : BSEEnclosed please find herewith update on acquisition.
Corporate Actions
No Upcoming Board Meetings
Alivus Life Sciences Ltd has declared 250% dividend, ex-date: 01 Sep 26
No Splits history available
No Bonus history available
No Rights history available